EC Granted Orphan Drug Designation to AR101 for Ehlers-Danlos Syndrome
The European Commission (EC) has recently granted its Orphan Drug designation to AR101, a PKCβ inhibitor for the treatment of Ehlers-Danlos syndrome (EDS). This decision was based off of a…